Sartorius AG (SRT) Receives Average Rating of “Hold” from Analysts

Shares of Sartorius AG (ETR:SRT) have earned an average rating of “Hold” from the eight analysts that are presently covering the stock, MarketBeat.com reports. Four investment analysts have rated the stock with a sell recommendation and four have assigned a hold recommendation to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is €114.88 ($133.58).

A number of analysts recently weighed in on the stock. Commerzbank set a €101.00 ($117.44) target price on shares of Sartorius and gave the stock a “sell” rating in a research note on Thursday, August 9th. UBS Group set a €142.00 ($165.12) target price on shares of Sartorius and gave the stock a “neutral” rating in a research note on Wednesday, August 8th. Warburg Research set a €141.00 ($163.95) target price on shares of Sartorius and gave the stock a “neutral” rating in a research note on Wednesday, September 5th. Finally, Kepler Capital Markets set a €111.00 ($129.07) target price on shares of Sartorius and gave the stock a “sell” rating in a research note on Wednesday, August 1st.

ETR:SRT opened at €98.00 ($113.95) on Monday.

Sartorius Company Profile

Sartorius Aktiengesellschaft provides pharmaceutical and laboratory equipment worldwide. The company operates through two divisions, Bioprocess Solutions, and Lab Products & Services. The Bioprocess Solutions division offers products, technologies, and services ranging from fermentation, cell cultivation, filtration, and purification to media storage and transportation for the biopharmaceutical industry.

Featured Story: What is a stock split?

Analyst Recommendations for Sartorius (ETR:SRT)

Receive News & Ratings for Sartorius Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sartorius and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply